Toxicity of CAR T-Cell Therapy for Multiple Myeloma
Acta Haematologica · 2024
DOI: 10.1159/000539134 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Acta Haematologica, 2024. Verfasst von Aimaz Afrough und 6 weiteren Autor:innen. Beteiligte Einrichtung: Myeloma, Waldenstrom's, and Amyloidosis Program, Hematologic Malignancies and Cellular Therapy Program, Simmons Comprehensive Cancer Center, UT South…. Hauptthemen laut MEDLINE: Multiple Myeloma, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background: Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) are novel chimeric antigen receptor (CAR)-T cell therapies targeting B-cell maturation antigen (BCMA), and both have recently gained approval by the US Food Drug Administration (FDA) for the treatment of relapsed and refractory multiple myeloma (RRMM). Summary: These therapies offer unprecedented responses in RRMM but present new challenges including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), non-ICANS neurotoxicity, cytopenias, infections, and hypogammaglobulinemia. Key Messages: In the evolving CAR-T landscape, a primary objective is to develop innovative strategies for managing associated toxicities. Through meticulous exploration of underlying mechanisms and tailored interventions, we aim to enhance safety and enable broader outpatient utilization. Refinement of protocols, biomarker identification, and robust monitoring are imperative for sustained efficacy. This comprehensive approach guarantees the continuous advancement and optimization of CAR-T therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Myeloma, Waldenstrom's, and Amyloidosis Program, Hematologic Malignancies and Cellular Therapy Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA.
- Hematologic Malignancies and Cellular Therapy Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA.
- Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Zitieren
APA
Afrough, A., Abraham, P. R., Turer, L., Kaur, G., Sannareddy, A., Hansen, D. K., & Anderson, L. D. (2024). Toxicity of CAR T-Cell Therapy for Multiple Myeloma. Acta Haematologica. https://doi.org/10.1159/000539134
Vancouver
Afrough A, Abraham PR, Turer L, Kaur G, Sannareddy A, Hansen DK, et al. Toxicity of CAR T-Cell Therapy for Multiple Myeloma. Acta Haematologica. 2024. doi:10.1159/000539134
BibTeX
@article{Afrough2024,
author = {Afrough, Aimaz and Abraham, Pearl Rajan and Turer, Laura and Kaur, Gurbakhash and Sannareddy, Aishwarya and Hansen, Doris K and Anderson, Larry D},
title = {Toxicity of CAR T-Cell Therapy for Multiple Myeloma},
journal = {Acta Haematologica},
year = {2024},
doi = {10.1159/000539134}
}
EUVIMED